Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) Q3 Earnings Beat Estimates

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) shares fell 9.09% despite the company posting better than expected third quarter financial results. The clinical-stage immunotherapy company reported a net loss of (-$13.4) million or (-$0.52) cents a share. Analyst were expecting a net loss of (-$0.63) cents a share.

Immune Design Corp (NASDAQ:IMDZ)

Q3 Financial Results

Investor confidence in Immune design has taken a hit in recent weeks, seen by the stock trading near all-time lows. The stock is down by more than 50% for the year.

Immune Design Corp (NASDAQ:IMDZ) posted revenues of $0.5 million for the three months ended September 30, 2017. The revenue is primarily attributable to collaboration revenues associated with the Sanofi G103 HSV vaccine product collaboration.

However, it was a decline from revenues of $8.2 million reported last year. Revenue for the corresponding period last year included $7 million in license revenue and $0.4 million in product sales associated with the Sanofi collaboration.

Revenue for the first six months of the year totaled $6.7 million down from $11.2 million for the corresponding period last year. Research and Development expenses in the third quarter totaled $10.2 million compared to $11.2 million for the corresponding period last year. The decrease was primarily attributed to a decline in licensing royalties and fees to other third parties.

Immune Design Corp (NASDAQ:IMDZ) exited the third quarter with cash and cash equivalent of $67.5 million compared to $110.4 million as of December 31, 2016.

Pipeline Development

During the quarter, Immune Design Corp (NASDAQ:IMDZ) achieved an important milestone in the development of its drug pipeline. The FDA approved the Phase 3 trial, design, and approval criteria for the company’s candidate drug for the treatment of synovial sarcoma, CMB305.

“In addition, at ESMO we presented interim analysis data from our ongoing randomized Phase 2 study of CMB305 and atezolizumab showing that patients receiving the combination therapy experienced greater clinical benefit and immune response than those receiving atezolizumab alone,” said CEO, Carlos Paya.

Immune Design Corp (NASDAQ:IMDZ) completed an underwritten follow-on public offering in Q3 that resulted in the sale of 22.4 million shares of common stock. Estimated net proceeds from the offering is $86.6 million. The company plans to use net proceeds from the offering to fund ongoing clinical programs and for working capital.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) Bounces off Lows

Immune Design Corp (NASDAQ:IMDZ)

Shares of Immune Design Corp (NASDAQ:IMDZ) gained 12.2% ahead of their much-awaited financial results for the third quarter, ended September 30, 2017. The clinical stage immunotherapy company will release the results on November 1, 2017, after the close of the U.S. markets.

Immune Design Corp (NASDAQ:IMDZ)

Earnings Expectations

Investor confidence in the stock has taken a hit this month as seen by the stock shedding more than 50% in its market value. The stock has come under pressure following the pricing of an underwritten public offering of 19.5 million shares at a price of $4.10 a share. Investors pushed the stock lower after the company offered the shares at a discount to the market price.

Last quarter, the immunotherapy company reported a positive earnings surprise of 16.92% outpacing the consensus estimates of average earnings beat of 12.94%. A similar performance with Q3 financial results could result in the stock bouncing back from current trading levels.

Increased implied volatility on Immune Design Corp (NASDAQ:IMDZ) November options is already fuelling suggestions of a potential big move in either direction. Analysts at Zack’s research currently rate the stock as a ‘hold’.

Immune Design Pipeline

Progress on the company’s pipeline candidates should have an impact on the stock’s direction of trade going forward. The company’s lead candidate drugs are CMB305 for the treatment of solid tumor and G100 for the treatment of merkel cell carcinoma.

Immune Design is evaluating CMB305 both as a monotherapy and in combination with Roche Holding Ltd. (ADR)(OTCMKTS:RHHBY) Tecentriq. G100 is being developed on the GLAAS platform in collaboration with Merck for the treatment of patients with non-Hodgkin’s lymphoma (NHL).

The European Medicine Agency has granted G100 Orphan Drug Designation for the treatment of NHL. The designation is expected to accelerate its development while also guaranteeing market exclusivity for up to 10 years.

Immune Design Corp (NASDAQ:IMDZ) has the financial power to accelerate the development of the two candidate drugs given the pricing of the $80 million public offering.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Immune Design Corp (NASDAQ:IMDZ) Awarded Orphan Drug Designation

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) shares fell 16% after the clinical stage company announced that the European Medicine Agency had granted its immunotherapy, G100, for non-Hodgkin’s lymphoma Orphan Drug Designation. The EMA designation is normally assigned to products targeting the treatment of rare medical conditions with prevalence of not more than 5 in 10,000 people.

The designation accords Immune Design Corp (NASDAQ:IMDZ) a string of benefits not limited to reduced fees for regulatory activities. The company also stands to enjoy protocol assistance when it comes to clinical trials. In addition, the clinical stage immunotherapy company will be granted 10 years of market exclusivity upon approval by regulators in the Union.

The company’s lead drug for the treatment of non-Hodgkin’s lymphoma has also been granted Orphan Drug Designation in the U.S by the Food and Drug Administration. Developed from Immune Design Corp (NASDAQ:IMDZ)’s GLAAS discovery platform, the candidate product is designed to activate innate and adaptive immunity in the tumor microenvironment.

IMDZ Stock Performance

Immune Design Corp (NASDAQ:IMDZ)

Immune Design Corp (NASDAQ:IMDZ) free fall in the market shows no signs of slowing down as the stock has shed more than 40% in market value since the start of the month. The stock is currently trading at levels last seen at the start of the year.

Declining investor’s sentiments on the stock follows reports that the company plans to initiate a Phase 3 study of cancer vaccine candidate CMB305 in NY-ESO-1. The timing of the study, slated for mid-2018, appears to have spooked investors. The stock has also been downgraded by analysts at Wells Fargo to a ‘Neutral’ – seen as another cause for alarm among investors.

Immune Design Pipeline

CMB305 is one of Immune Design primary candidates currently in multiple clinical trials in patients with soft tissue sarcoma. The product is being investigated as a monotherapy and in combination with Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s RHHBY Tecentriq.

“The trial will have progression-free survival (PFS) followed by overall survival (OS) as co-primary endpoints. If the PFS endpoint is successful, the FDA offered that it may support full approval of CMB305. Depending on the rate of events, final PFS analysis may occur as early as 24 months from the first patient dosed,” Immune Design in a statement.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $IMDZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.